zurück

Abemaciclib (re-assessment: breast cancer, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, in combination with aromatase inhibitors)

 

Subject:

  • Active Substance: Abemaciclib
  • Name: Verzenios®
  • Therapeutic area: Breast cancer
  • Pharmaceutical company: Lilly Deutschland GmbH

 

Time table:

  • Start: 01.01.2023
  • Final decision by G-BA: 15.06.2023

 

Final decision:

  • Hint for a minor additional benefit.